IRIS
ANDREONI, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 81.508
AS - Asia 11.832
EU - Europa 10.268
SA - Sud America 1.805
AF - Africa 264
OC - Oceania 52
Continente sconosciuto - Info sul continente non disponibili 31
Totale 105.760
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 81.142
SG - Singapore 5.476
CN - Cina 2.139
IT - Italia 1.974
BR - Brasile 1.494
RU - Federazione Russa 1.432
DE - Germania 1.402
HK - Hong Kong 1.112
UA - Ucraina 1.036
IE - Irlanda 1.035
KR - Corea 943
VN - Vietnam 904
FR - Francia 688
SE - Svezia 609
GB - Regno Unito 591
FI - Finlandia 490
PL - Polonia 340
JP - Giappone 302
IN - India 211
CA - Canada 209
NL - Olanda 164
BD - Bangladesh 112
ZA - Sudafrica 106
AR - Argentina 104
MX - Messico 102
ID - Indonesia 98
AT - Austria 97
TR - Turchia 91
BE - Belgio 88
ES - Italia 76
IQ - Iraq 75
CZ - Repubblica Ceca 64
PK - Pakistan 51
AU - Australia 48
EC - Ecuador 47
CO - Colombia 42
PH - Filippine 41
CL - Cile 38
VE - Venezuela 33
KG - Kirghizistan 31
MA - Marocco 31
SA - Arabia Saudita 25
UZ - Uzbekistan 25
CH - Svizzera 23
JO - Giordania 23
AE - Emirati Arabi Uniti 22
EU - Europa 21
IR - Iran 21
LT - Lituania 21
IL - Israele 19
PY - Paraguay 19
TN - Tunisia 19
GR - Grecia 18
KE - Kenya 18
EG - Egitto 17
JM - Giamaica 16
RO - Romania 16
KZ - Kazakistan 15
DZ - Algeria 14
TW - Taiwan 14
MY - Malesia 13
AL - Albania 12
ET - Etiopia 12
PE - Perù 12
HR - Croazia 10
TH - Thailandia 10
DK - Danimarca 9
NP - Nepal 9
PT - Portogallo 9
UY - Uruguay 9
A2 - ???statistics.table.value.countryCode.A2??? 8
BA - Bosnia-Erzegovina 7
HN - Honduras 7
NO - Norvegia 7
OM - Oman 7
AO - Angola 6
AZ - Azerbaigian 6
BH - Bahrain 6
LV - Lettonia 6
NG - Nigeria 6
RS - Serbia 6
SI - Slovenia 6
TT - Trinidad e Tobago 6
BG - Bulgaria 5
HU - Ungheria 5
LB - Libano 5
PA - Panama 5
SC - Seychelles 5
BO - Bolivia 4
CM - Camerun 4
DO - Repubblica Dominicana 4
GH - Ghana 4
MK - Macedonia 4
NZ - Nuova Zelanda 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
AM - Armenia 3
CR - Costa Rica 3
GA - Gabon 3
GE - Georgia 3
Totale 105.692
Salva come PNG Salva come JPEG
Città #
Woodbridge 21.632
Wilmington 21.418
Houston 15.552
Singapore 3.200
Fairfield 2.566
Chandler 1.860
Ashburn 1.832
Ann Arbor 1.816
San Jose 1.443
Hong Kong 1.093
Seattle 1.077
Beijing 879
Cambridge 870
Dublin 869
Jacksonville 812
Rome 697
Medford 648
New York 599
Dearborn 568
Santa Clara 473
The Dalles 466
Los Angeles 396
Council Bluffs 388
Lawrence 304
Ho Chi Minh City 279
Tokyo 274
Helsinki 256
Kraków 254
Moscow 232
Hanoi 227
Lauterbourg 211
Milan 210
San Diego 200
Buffalo 195
Dallas 190
Munich 161
São Paulo 161
Menlo Park 158
Orem 144
Zhengzhou 127
Nuremberg 117
London 110
Mülheim 97
Boardman 94
Brussels 87
Chicago 81
North Bergen 78
Redondo Beach 77
Phoenix 76
Chennai 74
Montreal 72
Frankfurt am Main 71
Jakarta 68
Warsaw 63
Denver 61
Toronto 60
Nanjing 59
Amsterdam 58
Johannesburg 57
Palo Alto 57
Atlanta 55
Brooklyn 52
Guangzhou 51
Falls Church 50
San Francisco 50
Shanghai 50
Stockholm 49
Redwood City 47
Rio de Janeiro 47
Manchester 46
Norwalk 45
Dong Ket 43
Hefei 43
Hangzhou 42
San Mateo 41
Verona 41
Poplar 38
Seoul 38
Da Nang 37
Mountain View 37
Vienna 37
Belo Horizonte 36
Brno 36
Boston 33
Ankara 32
Kunming 32
Mexico City 31
Baghdad 30
Creede 29
Curitiba 29
Haiphong 29
Lappeenranta 28
University Park 28
Columbus 27
Mumbai 27
Naples 26
Paris 26
Salt Lake City 26
Amman 21
Bari 21
Totale 87.740
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 577
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 574
Microbiologic characteristics and predictors of mortality in bloodstream infections in intensive care unit patients: A 1-year, large, prospective surveillance study in 5 Italian hospitals 537
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 532
18-Fluoro-2-deoxyglucose positron emission tomography-computed tomography: an additional tool in the diagnosis of prosthetic valve endocarditis. 519
Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals 513
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 507
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 504
Human herpesvirus-8 infection in pregnancy and labor: Lack of evidence of vertical transmission 499
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 487
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 485
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 484
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 484
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 481
Prognostic factors of long-term CD4+ count-guided interruption of antiretroviral treatment 479
A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects. 479
Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy 477
Infection with human herpesvirus type 8 and Kaposi's sarcoma in a central Italian area formerly endemic for malaria 476
Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens 474
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 473
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 473
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 472
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 468
Efficient and reproducible new semimicromethod for the detection and titration of HIV in human plasma 464
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (< 400 HIV-RNA cp/ml) during different antiretroviral regimens 463
Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing 463
A fatal case of invasive fungal sinusitis by Scopulariopsis acremonium in a bone marrow transplant recipient 462
HIV plasma viremia in 22 seropositive subjects [VALUTAZIONE DELLA VIREMIA PLASMATICA DA HIV IN 22 SOGGETTI SIERO-POSITIVI] 461
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 457
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 452
Multidrug resistance after lamivudine therapy for chronic hepatitis B 450
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 450
Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy. 450
Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART 448
Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy 448
Neutralizing antibodies against autologous human immunodeficiency virus type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment 447
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 447
Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy 445
Reduction of IFN-gamma and IL-2 production by peripheral lymphocytes of HIV-exposed seronegative subjects 444
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 444
Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations 443
A case of rhabdomiolysis associated with raltegravir use 443
High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. 443
Cortical sources of resting state electroencephalographic rhythms probe brain function in naïve HIV individuals 441
High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis 439
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 439
ellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy. 437
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 436
HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity 435
Human herpesvirus 8 and human herpesvirus 2 infections in prison population 433
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 433
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 432
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 432
Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (invirase) treatment 429
Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy 429
Five human immunodeficiency virus type 1 phenotypic variants with different MT-2 cell tropisms correlate with prognostic markers of disease 429
Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: impact on susceptibility to first-line strategies including Integrase strand-transfer inhibitors 429
Dapsone hypersensitivity syndrome complicated by Scedosporium apiospermum pneumonia in an immunocompetent patient. 428
Correlates of HIV, HBV, and HCV infections in a prison inmate population: Results from a multicentre study in Italy 427
Viral growth assay to evaluate the replicative capacity of HIV-1 isolates 427
Infection with human herpesvirus-8 and its correlation with hepatitis B virus and hepatitis C virus markers among rural populations in Cambodia 427
Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapy 426
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 426
Plasma Viremia Titration and RNA Quantitation in ICD-p24 Negative HIV Type-1-Infected Patients 426
Prevalence of HHV-8 infection in Albanian adults and association with HBV and HCV 424
Complication of nasal piercing by Staphylococcus aureus endocarditis: a case report and a review of literature. 424
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 422
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 422
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 421
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 421
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 420
Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon 420
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 420
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 419
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 418
Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: A cross-sectional evaluation 417
Primary human herpesvirus 8 infection in immunocompetent children. 417
Human herpesvirus 8 cytoviraemia rebound in a patient with Kaposi's sarcoma after a short interruption of efficient antiretroviral therapy. 417
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 416
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation 415
Prevalence trend and correlates of HHV-8 infection in HIV-infected patients 414
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 414
Biomarkers of monitoring and functional reserve of physiological systems over time in HIV: expert opinions for effective secondary prevention 414
HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy 412
Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. 412
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 412
Infection with human herpesvirus type 8 and human T-cell leukaemia virus type 1 among individuals participating in a case-control study in Havana City, Cuba 411
Once-a-day (QD) vs. Twice-daily (BID) Nevirapine as Simplification in PI-Treated Patients after 2 mos. of BID Induction 411
KSHV DNA viremia correlates with low CD4+ cell count in Italian males at the time of diagnosis of HIV infection 411
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors 411
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages 410
Dysplasia of Granulocytes in a Patient with HPV Disease, Recurrent Infections, and B Lymphopenia: A Novel Variant of WHIM Syndrome? 410
HBV, HCV, HDV AND HEV COINFECTIONS IN A COHORT OF HIV POSITIVE PATIENTS IN CAMEROON 409
Dual mixed (but not X4) tropic-HIV-1 isolates can replicate in human primary macrophages and are inhibited by CCR5- inhibitors 406
Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals 405
Non-B HIV type 1 subtypes: Replicative capacity and response to antiretroviral therapy 404
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 404
High rate of HIV isolation from plasma of asymptomatic patients through polyethylene glycol (PEG) treatment 402
Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS [1] 402
Development of cellulitis caused by Aeromonas hydrophila in allogeneic hematopoietic transplantation: a case report. 402
Totale 44.427
Salva come PNG Salva come JPEG
Categoria #
all - tutte 274.188
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 274.188
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021750 0 0 0 0 0 0 0 0 0 0 502 248
2021/20223.981 183 312 229 271 171 448 223 213 466 307 243 915
2022/20234.898 479 400 301 641 413 1.043 371 348 460 36 270 136
2023/20242.072 261 75 158 110 162 446 102 148 54 144 28 384
2024/20259.077 321 1.861 918 646 277 584 878 551 918 907 643 573
2025/202614.143 1.195 648 1.597 1.399 1.469 676 2.111 1.823 1.917 1.289 19 0
Totale 107.195